List view / Grid view
20 May 2016 | By Katie Sadler
NICE has announced it will not be recommending pertuzumab to treat HER2-positive breast cancer because it is uncertain of the long term benefits for patients.
12 May 2016 | By Victoria White, Digital Content Producer
Newly published data validate the distinct vascular remodelling activity of Halaven (eribulin) compared to bevacizumab in breast tumour tissue...
20 April 2016 | By Victoria White, Digital Content Producer
Pfizer has announced positive top-line results from the Phase III PALOMA-2 trial for Ibrance (palbociclib) in breast cancer...
11 March 2016 | By Victoria White
A trial has shown that lapatinib plus trastuzumab before surgery shrinks and may even destroy tumours in women with HER2+ breast cancer within 11 days. The EPHOS B trial studied 257 women with HER2 positive breast cancer in the short gap between initial diagnosis and surgery to remove their tumours.…
8 March 2016 | By Victoria White
The approval expands the use of Faslodex and offers additional options for US women with HR+, HER2- metastatic breast cancer…
3 March 2016 | By Victoria White
In a study, some 67% of 347 women given palbociclib plus fulvestrant showed clinical benefit compared with 40% of 174 women given placebo plus fulvestrant...
1 March 2016 | By Victoria White
The breast cancer treatment pipeline’s exceptional levels of activity and innovation may significantly alter the clinical and commercial landscape, says GBI Research...
23 February 2016 | By Victoria White
Ibrance is approved for the treatment of HR+, HER2- advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy...
17 February 2016 | By Victoria White
Eisai and PIQUR Therapeutics are to collaborate to conduct the Phase I/IIb clinical study of PIQUR’s PQR309 in combination with Eisai’s eribulin...
16 February 2016 | By Victoria White
Scientists have developed a test called the Ecosystem Diversity Index which combines methods used by ecologists with a powerful cancer imaging technique...
5 January 2016 | By Victoria White
GBI Research states that this strong growth will be primarily due to substantial increases in the prevalence of breast cancer, with rates of the disease expected to rise over the forecast period due to an aging population, changing lifestyles and higher survival rates...
17 December 2015 | By Victoria White
Genomic Health has announced results from multiple Oncotype DX breast cancer test studies that reconfirm the Oncotype DX test accurately predicts clinical outcomes in patients with early-stage invasive breast cancer...
11 December 2015 | By Victoria White
New data supports the previously shown ability of Eisai’s Halaven (eribulin) to reverse epithelial-to-mesenchymal transition...
1 December 2015 | By Victoria White
The assay has been selected by the International Breast Cancer Study Group (IBCSG) and the Breast International Group (BIG) to be part of a trial studying the effects of palbociclib in breast cancer...
17 November 2015 | By Victoria White
NICE has published final draft guidance not recommending the use of Kadcyla as a treatment for a type of advanced breast cancer because the price is too high...
